The B6-hTFRC/htau*P301S mouse model is a humanized model obtained by breeding B6-hTFRC(CDS) mice (Catalog No.: C001584) with B6-htau*P301S mice (Catalog No.: C001836). This model can be used for research on Alzheimer's disease (AD), Frontotemporal dementia (FTD), neurodegenerative diseases, and tumor development, aiding in the research of TFRC/MAPT-targeted drugs.

This strain is a mouse Mapt gene humanized model carrying P301S mutation and can be used for research on FTD and AD. The homozygous B6-htau*P301S mice are viable and fertile. In addition, based on the independently developed TurboKnockout fusion BAC recombination technology, Cyagen can also generate other hot mutation models (e.g., B6-htau*P301L mice) and provide customized services for specific mutations.

The B6-hCCR8 mouse is a humanized model, constructed by replacing the coding sequences of the endogenous mouse Ccr8 gene with the coding sequences of the human CCR8 gene. B6-hCCR8 mice can be used for research into the pathogenesis of allergic disorders, various cancers, chronic inflammatory conditions, and HIV-1 infection, as well as for the screening, development, and safety evaluation of CCR8-targeted drugs.

This strain is a humanized mouse F9 gene model, which can be used for preclinical evaluation of hemophilia B pathogenesis and therapeutic drugs. Homozygotes of this model are viable and fertile.

The B6-hTFRC/htau*P301L mouse model is a humanized model obtained by breeding B6-hTFRC(CDS) mice (Catalog No.: C001584) with B6-htau*P301L mice (Catalog No.: C001835). This model can be used for research on Alzheimer's disease (AD), Frontotemporal dementia (FTD), neurodegenerative diseases, and tumor development, aiding in the research of TFRC/MAPT-targeted drugs.

B6-h4-1BB/hPDL1 mice are TNFRSF9 and CD274 double humanized mouse models obtained by mating TNFRSF9 humanized mouse models (Catalog No. C001604) with CD274 humanized mouse models (Catalog No. C001235). They express human TNFRSF9 and CD274 genomic sequences under the control of mouse promoters. This model is a valuable tool for studying cancer immunotherapy. In addition, this model also provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting TNFRSF9 and CD274.

The B6-hIL4/hIL4RA mouse model is generated by crossing IL4 humanized mice (Catalog Number: C001628) with IL4R humanized mice (Catalog Number: C001629), resulting in a dual-humanized model. This model faithfully recapitulates the human IL-4/IL-4R signaling pathway, making it an invaluable tool for studying allergic diseases (e.g., asthma and atopic dermatitis), Th2 immune responses, parasitic infections, tumor immunology, and chronic inflammation. Furthermore, it serves as a robust preclinical platform for evaluating the efficacy and mechanisms of therapeutic agents targeting the IL-4/IL-4Rα pathway.

This strain is a humanized model of the mouse Pdl1 gene in which the gene sequence encoding the extracellular domain (immunoglobulin V-like, IgV-like) of mouse PD-L1 protein is replaced with the corresponding human PD-L1 gene sequence. B6-hPDL1-V(2) mice can be used for the research of PD-L1 targeted drug development screening, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms. It is important to note that B6-hPDL1-V(2) mice were engineered utilizing an identical genetic modification strategy as the B6-hPDL1-V strain (Catalog Number: C001420), with their sole distinction lying in their genetic background.

Slamf9 is located on chromosome 1 of mice. Nuclease Technology was used to design sgRNA; Slamf9 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Alkbh4 is located on chromosome 5 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Alkbh4 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.